Table 6.
Trace and bulk element supplementation in patients.
| Intervention | Disease | N (age in years) | Biomarkers | Effect of intervention | Ref. |
|---|---|---|---|---|---|
| 250 mg magnesium oxide +220 mg ZnSO4 2x/day, 12 wks, DB |
PCOS |
60 women (18–40) | TAC, GSH, MDA, NO, PCs |
GSH higher (*), PCs lower (*) |
[55] |
| 30 IG | |||||
| 30 PG | |||||
| 250 mg magnesium oxide + 400 IU vitamin E/day, 12 wks, DB |
PCOS |
60 women: | TAC, GSH, MDA, NO |
TAC and NO increased (#) |
[56] |
| 30 IG (26 ± 3.7) | |||||
| 30 PG (27.2 ± 7.1) | |||||
| 100 mg magnesium, 4 mg zinc, 400 mg calcium + 200 IU vitamin D 2x/day, 12 wks, DB |
PCOS |
60 women: | TAC, GSH, MDA, NO |
MDA lower (*), TAC higher (*) |
[57] |
| 30 PG (24.8 ± 4.8) | |||||
| 30 IG (23.8 ± 5.7) | |||||
| 200 μg/day chromium, 8 wks, DB | PCOS | 40 women (18–40) | TAC, GSH, MDA | TAC higher (*), MDA lower (*) | [58] |
| 200 μg selenium yeast/day, 4 wks, DB | cardiac bypass | 33 women: | TAC, GSH, MDA, NO | GSH higher (*), MDA lower (*) | [59] |
| 17 IG (61.2 ± 4.6) | |||||
| 16 PG (62.6 ± 11.6) | |||||
All biomarkers measurements in blood (unless otherwise stated); men and women included (unless otherwise stated); PG (placebo group), IG (intervention group). DB (double-blind), SB (single blind), NB (not blinded); only significant results are mentioned. Significant changes are marked by: (*) vs. PG; (+) vs. baseline; (#) vs. baseline and PG.